Suppr超能文献

四取代烷基硫代亚咪唑的多样化和通用的区域选择性合成作为 p38α 丝裂原活化蛋白激酶抑制剂。

A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38α Mitogen-Activated Protein Kinase Inhibitors.

机构信息

Institute of Pharmaceutical Sciences, Department of Medicinal and Pharmaceutical Chemistry, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.

Teva-ratiopharm, Graf-Arco-Str. 3, 89079 Ulm, Germany.

出版信息

Molecules. 2018 Jan 20;23(1):221. doi: 10.3390/molecules23010221.

Abstract

An alternative strategy for the synthesis of 1-aryl- and 1-alkyl-2-methylsulfanyl-4-(4-fluorophenyl)-5-(pyridin-4-yl)imidazoles as potential p38α mitogen-activated protein kinase inhibitors is reported. The regioselective -substitution of the imidazole ring was achieved by treatment of α-aminoketones with different aryl or alkyl isothiocyanates. In contrast to previously published synthesis routes starting from 2-amino-4-methylpyridine, the presented route is characterized by a higher flexibility and a lower number of steps. This strategy was also applied to access 1-alkyl-2-methylsulfanyl-5-(4-fluorophenyl)-4-(pyridin-4-yl)imidazoles in six steps starting from 2-chloro-4-methylpyridine.

摘要

报道了一种合成 1-芳基和 1-烷基-2-甲硫基-4-(4-氟苯基)-5-(吡啶-4-基)咪唑的替代策略,这些化合物可能是 p38α 丝裂原活化蛋白激酶抑制剂。通过用不同的芳基或烷基异硫氰酸酯处理α-氨基酮,实现了咪唑环的区域选择性取代。与以前从 2-氨基-4-甲基吡啶开始的发表的合成路线相比,所提出的路线具有更高的灵活性和更少的步骤。该策略还应用于从 2-氯-4-甲基吡啶出发,经过六步反应合成 1-烷基-2-甲硫基-5-(4-氟苯基)-4-(吡啶-4-基)咪唑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7611/6017033/ef065e4e901b/molecules-23-00221-g001.jpg

相似文献

4
Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.
ChemMedChem. 2010 Jul 5;5(7):1134-42. doi: 10.1002/cmdc.201000114.
6
An Angle on MK2 Inhibition-Optimization and Evaluation of Prevention of Activation Inhibitors.
ChemMedChem. 2019 Oct 4;14(19):1701-1709. doi: 10.1002/cmdc.201900303. Epub 2019 Aug 13.
9
Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10. doi: 10.1016/j.bmcl.2008.06.007. Epub 2008 Jun 6.
10
Benzothiazole based inhibitors of p38alpha MAP kinase.
Bioorg Med Chem Lett. 2008 Mar 15;18(6):1874-9. doi: 10.1016/j.bmcl.2008.02.011. Epub 2008 Feb 10.

引用本文的文献

本文引用的文献

1
2-Alkylsulfanyl-4(5)-aryl-5(4)-heteroarylimidazoles: An Overview on Synthetic Strategies and Biological Activity.
Arch Pharm (Weinheim). 2017 Dec;350(12). doi: 10.1002/ardp.201700258. Epub 2017 Nov 16.
3
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3.
J Med Chem. 2017 Jan 26;60(2):594-607. doi: 10.1021/acs.jmedchem.6b01180. Epub 2017 Jan 17.
5
p38 MAPK inhibitors: a patent review (2012 - 2013).
Expert Opin Ther Pat. 2014 May;24(5):535-54. doi: 10.1517/13543776.2014.894977. Epub 2014 Mar 10.
6
The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models.
Mol Cell Biol. 2013 Oct;33(19):3728-34. doi: 10.1128/MCB.00688-13. Epub 2013 Jul 29.
7
The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease.
J Signal Transduct. 2012;2012:649079. doi: 10.1155/2012/649079. Epub 2012 Jun 25.
8
A general and facile one-pot process of isothiocyanates from amines under aqueous conditions.
Beilstein J Org Chem. 2012;8:61-70. doi: 10.3762/bjoc.8.6. Epub 2012 Jan 10.
9
p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).
Expert Opin Ther Pat. 2011 Dec;21(12):1843-66. doi: 10.1517/13543776.2011.636737. Epub 2011 Nov 15.
10
Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
Bioorg Med Chem Lett. 2010 Nov 15;20(22):6671-5. doi: 10.1016/j.bmcl.2010.09.012. Epub 2010 Sep 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验